Showing 2271-2280 of 5696 results for "".
- SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and Other Chronic Ophthalmic Diseaseshttps://modernod.com/news/spyglass-pharma-completes-90-million-series-c-financing-to-advance-novel-treatments-for-glaucoma-and-other-chronic-ophthalmic-diseases/2481711/SpyGlass Pharma announced the closing of $90 million in Series C financing to enable the company to conduct multiple US clinical trials of SpyGlass’ drug delivery platform. The SpyGlass system has the potential to deliver multiple years of medical therapy to address significant unmet n
- Nicox Presents NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis at the World Glaucoma Congresshttps://modernod.com/news/nicox-presents-ncx-470-phase-3-mont-blanc-adaptive-design-data-and-additional-subset-analysis-at-the-world-glaucoma-congress/2481705/Nicox presented additional data on NCX 470 at the 10th World Glaucoma Congress (WGC) in Rome, Italy. “The large volume of data generated in the Mont Blanc phase 3 trial on NCX 470 has provided us with the opportunity to look in detail at patient subgroups to further
- The International Agency for the Prevention of Blindness (IAPB) Welcomes Over 300 International Delegates to Singaporehttps://modernod.com/news/the-international-agency-for-the-prevention-of-blindness-iapb-welcomes-over-300-international-delegates-to-singapore/2481690/The International Agency for the Prevention of Blindness (IAPB) has welcomed more than 300 delegates to Singapore for its "2030 IN SIGHT LIVE" event. Hosted in partnership with the Singapore Eye Research Institute (SERI), the event gathers experts and thought leaders from eye
- FDA Clearance Expands the Label of Eyenuk's EyeArt AI System for the Detection of DRhttps://modernod.com/news/fda-clearance-expands-the-label-of-eyenuks-eyeart-ai-system-for-the-detection-of-dr/2481685/Eyenuk has received FDA clearance to use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy (DR), adding to the already-cleared usage with Canon CR-2 AF and Canon CR-2 Plus AF cameras. The regulatory clearance of t
- New Analysis From N-MOmentum Clinical Trial of Uplinza Demonstrate Process that Could Improve Clinical Care Process for NMOSDhttps://modernod.com/news/new-analysis-from-n-momentum-clinical-trial-of-uplinza-demonstrate-process-that-could-improve-clinical-care-process-for-nmosd/2481680/Horizon Therapeutics announced the publication of a new analysis from the N-MOmentum clinical trial of Uplinza demonstrating the utility of an adjudication process that could improve clinical care decision-making in neuromyelitis optica spectrum disorder (NMOSD) through more accurate and consiste
- Study: Lab-Grown ‘Mini-Corneas’ Mimic Developing Human Corneashttps://modernod.com/news/study-lab-grown-mini-corneas-mimic-developing-human-corneas/2481678/Researchers at NYU Langone Health say three-dimensional, lab-grown “mini-corneas” resemble the developing human cornea, potentially making them a new tool for the study of corneal diseases. P
- Beacon Therapeutics Launches with Goal of Developing Gene Therapies for Retinal Diseaseshttps://modernod.com/news/beacon-therapeutics-launches-with-goal-of-developing-gene-therapies-for-retinal-diseases/2481673/Beacon Therapeutics has launched and will develop a new generation of gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness. Syncona Limited, with additional investors including OSE, has provided £96 million ($120 million) to fund the acqu
- FDA Approves Novaliq's Cyclosporine Eye Drop Vevye for Treatment of Dry Eye Diseasehttps://modernod.com/news/novaliq-announces-fda-approval-of-vevye-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2481664/Just 3 weeks after receiving FDA approval for dry eye drug Miebo, Novaliq has received FDA approval for Vevye (cyclosporine ophthalmic solution; formerly known as CyclASol) 0.1% for the treatment of the signs and symptoms of dry eye disease. Novaliq says Vevye is the first and only
- Cellusion Raises $21 Million to Advance iPS Cell-Derived Corneal Endothelial Cell Substitutehttps://modernod.com/news/cellusion-raises-21-million-to-advance-ips-cell-derived-corneal-endothelial-cell-substitute/2481659/Tokyo-based Cellusion announced that it has raised 2.83 billion yen ($21 million USD) in Series C Round financing. The funding will be used to promote its lead program—the development of iPS cell-derived corneal endothelial cell substitute (CLS001) to resolve the challenge of
- Aviceda Announces Dosing of First Patient With AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of GAhttps://modernod.com/news/aviceda-announces-dosing-of-first-patient-with-avd-104-a-novel-glyco-mimetic-nanoparticle-for-the-treatment-of-ga/2481647/Aviceda Therapeutics announced the dosing of its first patient with AVD-104 in its phase 2 SIGLEC trial by Ashkan Abbey, MD, of Texas Retina Associates in Dallas. This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong preclinical in